文献速递贫血与红细胞疾病淋巴瘤

上海地区淋巴瘤患者贫血的多中心调查与分析

[A multicenter investigation and analysis on anemia in lymphoma patients in Shanghai].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该多中心研究对上海4所综合医院2017年1月至2018年6月住院的501例淋巴瘤患者随访6个月,发现贫血患病率达62.7%,初治贫血占34.3%,新发贫血占42.1%。IPI评分3~5分及化疗是新发贫血的独立危险因素,贫血与疗效差及体能状态相关。

要点

  • 淋巴瘤患者贫血患病率高达62.7%,新发贫血发生率为42.1%。
  • IPI评分3~5分及化疗是新发贫血的独立危险因素。
  • 初治伴贫血的淋巴瘤患者疗效较无贫血患者差。

核心结论

  • 淋巴瘤患者贫血患病率及发病率高,贫血发生与严重程度同疗效及体能状态密切相关。

研究设计与样本

  • 多中心研究,纳入上海4所综合医院2017年1月至2018年6月住院的501例淋巴瘤患者,随访6个月。

主要发现

  • 501例中178例(35.5%)伴贫血,初治289例中贫血99例(34.3%),随访中新发贫血136例(42.1%),总患病率62.7%。
  • 初治淋巴瘤贫血发生与年龄、病理类型、骨髓浸润、IPI评分及Ann Arbor分期相关。
  • 初治伴贫血患者疗效差于无贫血患者。
  • 多因素分析显示IPI评分3~5分(P<0.001,OR=4.230,95%CI 2.339~7.650)及化疗(P<0.001,OR=11.049,95%CI 5.149~23.711)是新发贫血独立危险因素。
  • PS评分与贫血发生显著相关。

临床怎么用

  • 对淋巴瘤患者应监测贫血发生,尤其IPI评分3~5分及接受化疗者。
  • 贫血发生及严重程度可作为评估疗效及体能状态的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the occurrence and influencing factors of anemia in lymphoma patients and its effect on treatment. Methods: A total of 501 lymphoma patients, who were hospitalized in four general hospitals in Shanghai from January 2017 to June 2018, were followed up for six months. The clinical data about anemia were collected and statistically analyzed. Results: Among all the enrollment patients, there were 178 patients (35.5%) had anemia. Among 289 patients whom were initially treated for lymphoma, there were 99 patients (34.3%) with anemia. In the following-up time, there were 136 new cases (42.1%) of anemia. The total prevalence of anemia was 62.7%. The univariate analysis indicated that the anemia incidence for initially treated lymphoma patients was significantly related to their age, pathological type, bone marrow infiltration, IPI scores and Ann Arbor stage. The response to initially treatment in lymphoma patients with anemia was inferior to those without anemia. The multivariate analysis indicated that IPI scores 3-5 points (P<0.001, OR=4.230, 95%CI 2.339-7.650) and chemotherapy treatment (P<0.001, OR=11.049, 95%CI 5.149-23.711) were the independent influential factors to the emerging anemia incidence. PS score used to evaluate patient physical condition was obviously related to the anemia occurrence. Conclusion: Lymphoma patients have a high prevalence and incidence of anemia. The occurrence and severity of anemia are closely related to the efficacy and physical condition of lymphoma patients. 目的: 研究淋巴瘤患者贫血的发生情况、影响因素及其对疗效的影响。 方法: 对上海地区4所综合性医院2017年1月至2018年6月住院的501例淋巴瘤患者进行6个月随访,统计分析贫血相关临床资料。 结果: 501例淋巴瘤患者中178例(35.5%)伴有贫血;初治淋巴瘤289例,其中贫血患者99例(34.3%);调查过程中新发贫血136例(42.1%);整个调查过程,贫血患病率达62.7%。单因素分析结果显示:初治淋巴瘤患者贫血发生与年龄、病理类型、有无骨髓浸润、国际预后指数(IPI)评分及Ann Arbor分期相关;初治淋巴瘤伴有贫血的患者较无贫血患者疗效差。多因素分析结果显示:IPI评分3~5分(P<0.001,OR=4.230,95%CI 2.339~7.650)及化疗(P<0.001,OR=11.049,95%CI 5.149~23.711)是新发贫血的独立危险因素,患者的体能状态评分(PS评分)与贫血显著相关。 结论: 淋巴瘤患者贫血发病率及患病率高,贫血的发生与严重程度与淋巴瘤患者疗效及体能状态密切相关。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shen J, Hao SG, Chen BB, et al. [A multicenter investigation and analysis on anemia in lymphoma patients in Shanghai]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32135628. doi:10.3760/cma.j.issn.0253-2727.2020.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。